Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial

Authors

Institutions

Publication Details

Journal
Expert Opinion on Investigational Drugs
Published
2024-08-22
DOI
https://doi.org/10.1080/13543784.2024.2394186
Citations
2
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.48

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial

Jaeseong Oh, Lei Tang, In‐Jin Jang, Yingxin Li et al.
2 citations
Expert Opinion on Investigational Drugs
Complement system in diseases
0.48
article

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial

Jaeseong Oh, Lei Tang, In‐Jin Jang, Yingxin Li, Joo Young Na, Yunting Zhu, Amy Zhao
article en
2 citations

Abstract

No abstract available for this paper.
Expert Opinion on Investigational DrugsVol. 33(10)
Seoul National University (KR), Seoul National University Hospital (KR), Sanofi (China) (CN), The Ohio State University (US)
Sanofi
Openalex Percentile: Top 35%
Complement system in diseases
0.48
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.